PER® New York Lung Cancer Symposium | Conference

Dr. Hanna on Challenges With Consolidation Immunotherapy in Lung Cancer

November 10th 2019

Nasser H. Hanna, MD, discusses challenges in consolation immunotherapy for patients with lung cancer.

Role of Neoadjuvant Immunotherapy Being Refined in Resectable NSCLC

November 10th 2019

Neoadjuvant immunotherapy can offer promise to patients with resectable non–small cell lung cancer, but further investigation is required for optimal use, Tina Cascone, MD, PhD, said in a presentation during the 14th Annual New York Lung Cancers Symposium®.

Neoadjuvant Approaches Showcase Advantages in NSCLC

November 10th 2019

Based on efficacy, tolerability, and practicality, neoadjuvant therapy in lung cancer offers significant advantages over adjuvant treatment, said Jamie E. Chaft, MD, in a presentation during the 14th Annual New York Lung Cancers Symposium®. However, she added, adjuvant treatment predominantly remains the standard of care at many cancer centers, she said.

Levy Lends Insight on Evolving Treatment Strategies in Lung Cancer

November 9th 2019

Benjamin P. Levy, MD, discusses therapeutic strategies for patients with oncogenic-driven and nondriver non–small cell lung cancer.

More Data Needed on Changing Systemic Therapy in NSCLC

November 13th 2018

There is limited data on when and whether oncologists should change systemic therapy for patients with non–small cell lung cancer, but some studies provide useful guidance.

Biomarkers and Histology Play Key Roles in Frontline Metastatic NSCLC Options

November 13th 2018

In light of recent advancements, the current paradigm for choosing first-line therapy for patients with metastatic non–small cell lung cancer who do not harbor an actionable driver oncogene depends upon PD-L1 expression level and histology.

Herbst Highlights Next Steps With Immunotherapy in Lung Cancer

November 13th 2018

Roy S. Herbst, MD, PhD, discusses where future research is headed for immunotherapy in lung cancer.

Dr. Hanna on Consolidation Immunotherapy in Stage III NSCLC

November 13th 2018

Nasser Hanna, MD, Tom and Julie Wood Family Foundation Professor of Lung Cancer Clinical Research, at Indiana University Melvin and Bren Simon Cancer Center, discusses the efficacy of consolidation immunotherapy in patients with stage III non–small cell lung cancer.

Dr. Herbst on Immune Resistance in Lung Cancer

November 12th 2018

Roy S. Herbst, MD, PhD, chief of medical oncology, professor of medicine, Yale Cancer Center, Smilow Cancer Hospital, discusses mechanisms of immune resistance for patients with lung cancer.

Broad Panel NGS Testing Grows in Value for NSCLC

November 11th 2018

Although driver mutations have been identified for significant NSCLC subsets, patients with metastatic disease benefit from broad panel next-generation sequencing testing because of the growing clinical relevance of less common alterations and gene signatures.

Dr. Perez-Soler on Efficiency of NGS in Lung Cancer

November 11th 2018

Roman Perez-Soler, MD, chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore Medical Center, discusses the efficiency of next-generation sequencing in lung cancer.

Camidge Breaks Down Oncogene-Driven NSCLC

November 11th 2018

D. Ross Camidge, MD, PhD, discusses the crowded landscape of oncogene-driven non–small cell lung cancer.

Dr. Borghaei on Second-Line Therapy in SCLC

November 10th 2018

Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the evolving second line of treatment in small cell lung cancer.

Dr. Kris on Adjuvant Systemic Therapy in NSCLC

November 10th 2018

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses adjuvant systemic therapy in patients with non–small cell lung cancer.

Dr. Camidge on Optimal Therapy in EGFR+ NSCLC

November 10th 2018

D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses optimal treatment regimens for patients with EGFR-positive non–small cell lung cancer.

Acquired Resistance Remains Key Challenge in Oncogene-Driven NSCLC

November 9th 2018

Balazs Halmos, MD, MS, discusses overcoming acquired resistance and other next steps needed to advance the oncogene-driven non–small cell lung cancer paradigm.

Uncertainty Surrounds Nondriver NSCLC Treatment After Progression

November 9th 2018

Hossein Borghaei, DO, MS, discusses current and potential therapeutic approaches for patients with non-oncogene driven lung cancer who progress on frontline treatment.

Drilon Sheds Light on Lesser-Known Markers in NSCLC

November 9th 2018

Alexander E. Drilon, MD, discusses developing markers in the non–small cell lung cancer paradigm.

Dr. Kris on Sequencing Challenges in Lung Cancer

November 17th 2016

Mark G. Kris, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses challenges associated with sequencing in the treatment of patients with lung cancer.

Optimizing Frontline Immunotherapy in NSCLC

November 15th 2016

Immunotherapy continues to revolutionize the field of non–small cell lung cancer, with researchers now focusing on the optimal use of immune agents in the frontline setting.